Tiziana Life Sciences Ltd

Healthcare · Biotechnology · United Kingdom

Last price 0.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.42M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune an...